常见肝病的单基因与多基因风险:临床意义
本综述总结遗传检测在临床肝病中的作用,包括单基因驱动因素及常见变异和多基因风险评分的应用。特定人群如隐源性肝硬化和瘦型MASLD患者可能富集单基因病因,而PNPLA3等变异有助于评估纤维化进展风险。多基因风险评分在预测纤维化进展和肝脏相关事件方面有适度改善,但人群筛查性能有限。
要点
- 隐源性肝硬化和瘦型MASLD患者应考虑单基因病因检测。
- PNPLA3、TM6SF2、HSD17B13等变异可用于评估纤维化进展风险。
- 多基因风险评分联合临床因素可适度改善风险预测,但不足以人群筛查。
核心结论
- 遗传风险联合临床和环境因素可能实现肝病预后和治疗的个体化。
研究设计与样本
- 综述,总结遗传检测在临床肝病中的角色及多基因风险评分的应用。
主要发现
- 隐源性肝硬化和瘦型MASLD患者可能富集单基因驱动因素。
- PNPLA3、TM6SF2、HSD17B13等变异有助于判断纤维化进展和肝硬化风险。
- 多基因风险评分在MASLD和ALD中预测纤维化进展和肝脏相关事件有适度改善,联合临床因素时更明显。
- 多基因风险评分单独对肝细胞癌诊断准确性有限,可能需要结合临床特征和多组学生物标志物的复杂模型。
关键数值与推荐
- 多基因风险评分在MASLD和ALD中预测纤维化进展和肝脏相关事件有适度改善。
- 多基因风险评分单独对肝细胞癌诊断准确性有限。
临床怎么用
- 对隐源性肝硬化和瘦型MASLD患者考虑单基因病因检测。
- 可将PNPLA3、TM6SF2、HSD17B13等变异纳入纤维化进展风险评估。
- 多基因风险评分应与临床风险因素和合并症整合使用。
局限性
- 基因组数据集祖先多样性有限。
- 变异多效性。
- 成本效益问题。
- 需要与其他组学和电子病历整合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The burden of chronic liver disease is rapidly increasing worldwide, driven primarily by metabolic dysfunction-associated steatotic liver disease, metabolic and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD). Genetic predisposition contributes substantially to variability in disease onset, progression, and outcomes, and recent advances in genomic discovery have brought polygenic risk scores (PRSs) and targeted sequencing closer to clinical relevance. This review summarizes the role of genetic testing in clinical hepatology, including monogenic drivers of disease and the growing role of common variants and PRS. Specific populations, including patients with cryptogenic cirrhosis and lean metabolic dysfunction-associated steatotic liver disease, may be enriched for monogenic drivers of disease. In addition, patients with chronic liver disease may benefit from incorporation of genetic risk scores, including PNPLA3, TM6SF2, HSD17B13, and other key variants in determining risk for fibrosis progression and cirrhosis. Across metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease, PRSs demonstrate modest improvements in predicting fibrosis progression and liver-related events, especially when integrated with clinical risk factors and comorbidities. However, their performance remains limited for population-level screening. Similarly, PRS alone has limited diagnostic accuracy for hepatocellular carcinoma and more complex models with clinical features and multiomic biomarkers are likely needed. Emerging therapies targeting PNPLA3 and HSD17B13 variants represent a paradigm shift toward genetically informed treatment. Yet challenges remain, including limited ancestral diversity in genomic datasets, pleiotropic effects of variants, cost-effectiveness, and the need for integration with other omics and electronic medical records. As evidence matures, combining genetic risk with clinical and environmental factors may enable more personalized approaches to prognostication and therapy in liver disease.
引用
- Ajmera V, Huang DQ, Chen VL, et al. Monogenic and Polygenic Risk in Common Liver Diseases: Implications for Clinical Care. Gastroenterology. 2026. PMID: 41932449. doi:10.1053/j.gastro.2026.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。